Bionet (1784) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bionet (1784) has a cash flow conversion efficiency ratio of 0.023x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$51.22 Million ≈ $1.61 Million USD) by net assets (NT$2.20 Billion ≈ $69.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 1784 market cap overview for the company's overall valuation and market capitalisation.
Bionet - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Bionet's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bionet Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bionet ranked by their cash flow conversion efficiency. Explore Bionet earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tsang Yow Industrial Co Ltd
TW:1568
|
0.033x |
|
Mobile Infrastructure Corporation
NASDAQ:BEEP
|
-0.010x |
|
Sound Financial Bancorp Inc
NASDAQ:SFBC
|
0.018x |
|
GKW Limited
NSE:GKWLIMITED
|
-0.001x |
|
Tainergy Tech Co Ltd
TW:4934
|
-0.035x |
|
Scandinavian Astor Group AB
ST:ASTOR
|
0.053x |
|
Kingwaytek Technology Co Ltd
TWO:6516
|
-0.016x |
|
SkyWorld Development Berhad
KLSE:5315
|
-0.182x |
Annual Cash Flow Conversion Efficiency for Bionet (2017–2025)
The table below shows the annual cash flow conversion efficiency of Bionet from 2017 to 2025. View current stock price of Bionet for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$2.26 Billion ≈ $71.12 Million |
NT$148.04 Million ≈ $4.66 Million |
0.066x | -10.97% |
| 2024-12-31 | NT$2.40 Billion ≈ $75.48 Million |
NT$176.49 Million ≈ $5.56 Million |
0.074x | -17.13% |
| 2023-12-31 | NT$1.72 Billion ≈ $54.26 Million |
NT$153.09 Million ≈ $4.82 Million |
0.089x | +24.41% |
| 2022-12-31 | NT$1.32 Billion ≈ $41.74 Million |
NT$94.65 Million ≈ $2.98 Million |
0.071x | +577.37% |
| 2021-12-31 | NT$1.32 Billion ≈ $41.45 Million |
NT$13.88 Million ≈ $437.23K |
0.011x | -81.54% |
| 2020-12-31 | NT$1.29 Billion ≈ $40.62 Million |
NT$73.66 Million ≈ $2.32 Million |
0.057x | +2698.56% |
| 2019-12-31 | NT$1.31 Billion ≈ $41.19 Million |
NT$2.67 Million ≈ $84.09K |
0.002x | +121.09% |
| 2018-12-31 | NT$1.34 Billion ≈ $42.22 Million |
NT$-12.97 Million ≈ $-408.78K |
-0.010x | +46.69% |
| 2017-12-31 | NT$1.37 Billion ≈ $43.21 Million |
NT$-24.91 Million ≈ $-784.83K |
-0.018x | -- |
About Bionet
BIONET Corp. engages in cell therapy, regenerative medicine, medical big data, gene testing, and sales of biological and scientific information hardware and software business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells, as well as skin … Read more